Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Costs and Expenses:
General and administrative	$ 10,143	$ 8,074	$ 6,013
Research and development	29,109	32,906	14,489
Total Operating Costs and Expenses	39,252	40,980	20,502
Loss from Operations	(39,252)	(40,980)	(20,502)
Other Income (Expense):
Change in fair value of warrant liability	11,412	(3,811)	620
Other income	0	0	95
Interest income	37	6	3
Total Other Income (Expense)	11,449	(3,805)	718
Net Loss	(27,803)	(44,785)	(19,784)
Net Loss Attributable to Non-controlling Interest	(548)	(1,048)	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (27,255)	$ (43,737)	$ (19,784)
Loss Per Share - Basic and Dilutive	$ (0.29)	$ (0.54)	$ (0.32)
Net Income (Loss) Per Share - Basic and Dilutive
Weighted average number of shares outstanding during the period - Basic and Dilutive	94,290,436	80,705,692	61,945,356